Preterm Nutrition

Overview

• Definition: Preterm nutrition refers to the specialized nutritional support provided to infants born before 37 weeks of gestation. This support aims to meet the unique metabolic and developmental needs of these vulnerable infants, optimizing growth, neurodevelopmental outcomes, and reducing morbidities, given their immature organ systems and limited nutrient reserves.
• Epidemiology: Globally, approximately 15 million infants are born preterm each year, representing about 1 in 10 births. Nutritional challenges are directly proportional to the degree of prematurity, with very low birth weight (VLBW, <1500g) and extremely low birth weight (ELBW, <1000g) infants facing the most significant nutritional hurdles and at highest risk for growth failure.
• Classification:
  • By gestational age: Extremely preterm (<28 weeks), Very preterm (28-32 weeks), Moderate to late preterm (32-37 weeks).
  • By feeding route: Enteral (oral/gavage), Parenteral (intravenous), or combined.
  • By feeding type: Human milk (maternal, donor), Formula (preterm, standard).

Pathophysiology

• Mechanism: Preterm infants have high nutritional demands due to rapid growth (comparable to intrauterine rates) but limited nutrient stores (esp. fat, glycogen, micronutrients), immature organ systems (gastrointestinal, renal, hepatic, pulmonary), and high metabolic rates. They often experience significant catabolism acutely post-birth. Their GI tract is immature, leading to difficulties with digestion, absorption, and motility. Renal immaturity affects electrolyte and fluid balance. Hepatic immaturity can impact glucose homeostasis and bile acid synthesis.
• Risk Factors:
  • Extreme prematurity: Increased immaturity, higher nutritional needs.
  • Low birth weight/SGA: Reduced nutrient reserves.
  • Perinatal complications: Hypoxia-ischemia, sepsis, necrotizing enterocolitis (NEC), surgical interventions.
  • Respiratory distress syndrome (RDS)/BPD: Increased energy expenditure, fluid restriction.
  • Cardiac abnormalities (e.g., PDA): Fluid restriction, increased metabolic demand.
  • Maternal factors: Poor maternal nutrition, preeclampsia, chorioamnionitis.
  • Delayed enteral feeding initiation: Prolonged reliance on parenteral nutrition.
• Protective Factors:
  • Maternal human milk (MHM): Bioactive factors, immune protection, improved gut maturation, reduced NEC.
  • Early aggressive parenteral nutrition (PN): Prevents catabolism, provides essential nutrients.
  • Gradual advancement of enteral feeds: Allows for gut adaptation.
  • Standardized feeding protocols: Ensures consistent, evidence-based approach.
  • Fortification of human milk: Meets higher nutrient demands of preterms.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Growth failure/Poor weight gain: Failure to meet target growth velocity (typically 15-20 g/kg/day).
  • Nutrient deficiencies: Specific signs depending on the deficiency (e.g., rickets, anemia, osteopenia).
  • Feeding intolerance: Gastric residuals, abdominal distension, emesis.
• Early Signs:
  • Weight loss exceeding physiological norms (usually >10-15% of birth weight).
  • Hypoglycemia/hyperglycemia.
  • Electrolyte imbalances (e.g., hyponatremia, hyperkalemia).
  • Jaundice (prolonged/exacerbated).
• Advanced Signs:
  • Frank malnutrition (cachexia, lack of subcutaneous fat).
  • Osteopenia of prematurity (fractures).
  • Refractory anemia.
  • Persistent feeding intolerance leading to prolonged PN.
  • Cholestasis (PN-associated liver disease, if on prolonged PN).
• Atypical Presentations:
  • Subtlety of signs, especially in critically ill infants (e.g., mild irritability or lethargy can be a sign of electrolyte imbalance or severe calorie deficit).
  • Lack of weight gain despite adequate calorie intake, suggesting malabsorption or increased losses.

Physical Examination

• Inspection:
  • Growth: Head circumference, length, weight plotting on Fenton growth charts.
  • Body composition: Assessment of subcutaneous fat, muscle wasting.
  • Skin: Pallor (anemia), jaundice, edema, skin breakdown from frequent IVs.
  • Abdomen: Distension (feeding intolerance, NEC), bowel loops visible.
  • Bone: Rachitic rosary, frontal bossing (severe rickets), bowing of long bones.
• Palpation:
  • Abdomen: Tenderness, masses, firmness (NEC).
  • Fontanelle: Sunken (dehydration), bulging (hydrocephalus or increased intracranial pressure).
• Special Tests:
  • Anthropometric measurements: Daily weights, weekly or bi-weekly length and head circumference.
  • Feeding assessments: Evaluation of suck, swallow, breath coordination, gastric residual volume.

Diagnostic Approach

History Taking

• Key Questions:
  • Gestation at birth, birth weight, and current age/weight.
  • Maternal history: Pregnancy complications, maternal nutrition, medications.
  • Feeding history: Type (maternal milk, donor milk, formula, fortifiers), volume, frequency, method (gavage, oral), tolerance, gastric residuals, emesis, stool patterns.
  • Fluid balance: Intake, output, estimated losses.
  • Energy expenditure: Respiratory support, surgical procedures, sepsis, temperature regulation.
  • Current medications: Diuretics, steroids, H2 blockers, proton pump inhibitors.
  • Growth velocity: Trend over time.
• Red Flags:
  • Sudden change in feeding tolerance (increased residuals, vomiting, bloody stools).
  • Abdominal distension, tenderness, or discoloration.
  • Rapid weight loss or sudden cessation of weight gain.
  • Significant electrolyte derangements.
  • Persistent glucose dysregulation.

Laboratory Tests

• First-Line:
  • Daily electrolytes, BUN, creatinine: During acute phase, particularly on PN or active fluid management.
  • Weekly electrolytes, calcium, phosphorus, magnesium: Essential for monitoring bone mineralization and preventing refeeding syndrome.
  • Weekly alkaline phosphatase (ALP): Screen for osteopenia of prematurity. Higher levels signify increased bone turnover.
  • Weekly liver function tests (LFTs), direct bilirubin: Monitor for cholestasis, especially with PN.
  • Complete blood count (CBC): Assess for anemia, monitor for infection.
  • Blood glucose: Regular monitoring, especially with PN or critical illness.
• Confirmatory:
  • Serum protein, albumin, prealbumin: Indicators of nutritional status (though acute phase reactants can confound interpretation).
  • Nutrient levels: 25-hydroxyvitamin D (25(OH)D) to confirm deficiency/sufficiency. Trace elements (zinc, copper, selenium) if deficiency suspected or on prolonged PN.
  • Urine calcium/creatinine ratio: High ratio can indicate excessive calcium excretion, contributing to osteopenia.
• Monitoring:
  • Regular anthropometrics (weight daily, length/HC weekly).
  • Growth chart plotting (Fenton, WHO for post-discharge).
  • Repeat labs based on initial findings and clinical changes.

Imaging

• Recommended:
  • Bone densitometry (DEXA or peripheral quantitative CT): Not routinely used for screening but can confirm severe osteopenia of prematurity if fractures are suspected or ALP is persistently elevated.
  • Abdominal radiographs: As needed for suspected NEC (e.g., pneumatosis intestinalis).
• Advanced:
  • Cranial ultrasound: To assess for brain injury that may impact feeding or neurological development.

Management

Acute Management (First 72 hours)

• Immediate:
  • Stabilize hemodynamic and respiratory status: Crucial before initiating aggressive nutrition.
  • Early initiation of amino acids: Within the first 24 hours (1.5-3 g/kg/day) to prevent catabolism, especially in ELBW/VLBW infants.
  • Dextrose infusion: To maintain normoglycemia; typically 6-8 mg/kg/min glucose infusion rate (GIR).
  • Lipid emulsion: Within 24-48 hours (0.5-1 g/kg/day, increasing to 3-4 g/kg/day) to prevent essential fatty acid deficiency and provide calories.
  • Fluid management: Initially restricted (80-100 mL/kg/day) in ELBW/VLBW infants to manage pulmonary edema and patent ductus arteriosus (PDA), gradually increased.
• Stabilization:
  • Gradual advancement of PN: Increase amino acids (to 3.5-4 g/kg/day), lipids (to 3-4 g/kg/day), glucose (GIR 10-14 mg/kg/min) to meet target energy and protein needs.
  • Micronutrient supplementation: Add multivitamins and trace elements to PN as clinically indicated.
  • Start minimal enteral nutrition (MEN)/trophic feeds: Small volumes (10-20 mL/kg/day) of human milk (maternal or donor) to promote gut maturation and enzyme activity, usually within 24-48 hours, even if on ventilatory support.
• Emergency:
  • Management of hyperglycemia/hypoglycemia: Adjust glucose infusion rate or administer insulin/glucagon.
  • Management of severe electrolyte disturbances: Correct as per standard protocols.
  • Management of suspected necrotizing enterocolitis (NEC): NPO, antibiotics, surgical consultation.

Chronic Management

• Pharmacological:
  • Vitamin D supplementation: 400-800 IU/day from birth, increasing to 800-1000 IU/day if osteopenia is present.
  • Iron supplementation: 2-4 mg/kg/day elemental iron starting by 2-4 weeks of age (or earlier if on erythropoietin), usually by oral route.
  • Calcium and phosphorus supplementation: Often incorporated into human milk fortifiers or preterm formulas. If severe osteopenia, may require additional oral supplementation.
  • Multivitamins: Standard preterm multivitamin with trace elements if not on PN or to bridge gaps in diet.
• Non-pharmacological:
  • Human milk feeding: Fortified maternal human milk (MHM) or donor human milk (DHM). Fortification is crucial for VLBW infants to meet energy, protein, calcium, and phosphorus needs.
  • Preterm formula: Used when human milk is unavailable or insufficient; provides higher protein, calorie, and mineral content than standard infant formula.
  • Enteral feeding advancement: Gradually increase volume and concentration (if fortifying), monitoring for feeding intolerance. Target feeding volumes typically 150-180 mL/kg/day.
  • Close monitoring of growth: Daily weights, weekly length/head circumference, plotted on condition-specific growth charts (e.g., Fenton growth charts for prematurity). Target intrauterine growth rates (15-20 g/kg/day weight gain, 0.9-1.1 cm/week length, 0.6-0.8 cm/week head circumference).
  • Kangaroo mother care: Promotes human milk production and infant feeding.
• Monitoring:
  • Regular growth assessments.
  • Scheduled lab monitoring: Electrolytes, ALP, LFTs, CBC.
  • Feeding tolerance assessment: Gastric residuals, emesis, abdominal distension, stool pattern.
  • Neurodevelopmental follow-up: To assess impact of nutrition on developmental outcomes.

Treatment Algorithms

• First-Line:
  1. Early aggressive PN (Amino acids, glucose, lipids, electrolytes, vitamins, trace elements) within first 24-48 hours post-birth.
  2. Concurrent MEN/trophic feeds with human milk (MHM preferred, then DHM) at 10-20 mL/kg/day.
  3. Gradual advancement of enteral feeds: Increase volume of human milk as tolerated.
  4. Fortification of human milk: Once feeding volumes reach 80-100 mL/kg/day, or earlier based on unit protocol, to meet nutrient targets (e.g., human milk fortifier powder).
  5. Transition to full enteral feeds and discontinuation of PN as soon as safely possible.
• Second-Line:
  • Preterm formula: If human milk is unavailable, insufficient, or contraindicated; initiate with gradual transition.
  • Specialized formulas: For specific conditions (e.g., hydrolyzed protein formula for malabsorption, concentrated formula for fluid restriction).
  • Individualized micronutrient supplementation: If specific deficiencies are identified despite general supplementation.
• Refractory Cases:
  • Refractory feeding intolerance: Consider specialized GI referrals, prokinetics (e.g., erythromycin, metoclopramide as last resort due to side effects), parenteral nutrition dependence.
  • Severe growth failure: Intensive nutritional consultations, consideration of higher calorie/protein formulations, ruling out underlying systemic illness.
  • PN-associated cholestasis: Minimize gut rest, cycle PN if possible, use specialized PN lipid emulsions (e.g., fish oil-based), consider ursodiol.

Complications

• Common:
  • Growth failure/Extrauterine growth restriction (EUGR): Failure to achieve target growth.
  • Osteopenia of prematurity: Generalized reduction in bone mineralization.
  • Anemia of prematurity: Multifactorial, often exacerbated by insufficient iron intake.
  • Feeding intolerance: Gastric residuals, emesis, abdominal distension.
  • Hypoglycemia/Hyperglycemia: Common in the acute phase, associated with glucose dysregulation.
  • Electrolyte imbalances: Particularly sodium, potassium, calcium, phosphorus.
• Serious:
  • Necrotizing enterocolitis (NEC): Inflammatory bowel disease causing gut necrosis.
  • Parenteral Nutrition-Associated Liver Disease (PNALD)/Cholestasis: Prolonged PN disrupts enterohepatic circulation.
  • Central line-associated bloodstream infections (CLABSI): Risk with prolonged PN.
  • Specific nutrient toxicities: E.g., hypervitaminosis A/D.
  • Refeeding syndrome: Rapid reintroduction of nutrition in severely malnourished individuals, leading to electrolyte shifts and cardiac/neurologic complications.
• Long-term:
  • Neurodevelopmental impairment: Associated with poor early growth and specific nutrient deficiencies.
  • Metabolic syndrome: Potential long-term risk of obesity, diabetes, cardiovascular disease.
  • Chronic kidney disease: If severe electrolyte imbalances or drug toxicities occurred.

Prognosis

• Factors:
  • Degree of prematurity: ELBW/VLBW infants have higher nutritional needs and risks.
  • Adequacy of early aggressive nutrition: Impacts early growth and long-term neurodevelopment.
  • Availability and use of human milk: Reduces NEC, improves feeding tolerance.
  • Severity of comorbidities: RDS, BPD, sepsis, NEC, cardiac issues increase nutritional challenges.
  • Development of complications: NEC, PNALD, sepsis worsen outcomes.
  • Post-discharge nutrition: Continued adherence to specialized feeding plans.
• Survival: Directly correlated with gestational age and birth weight. Improved nutritional strategies have contributed to increased survival rates, particularly for ELBW infants.
• Quality of Life: Optimized nutrition is crucial for promoting brain growth and reducing the incidence and severity of neurodevelopmental impairments (cerebral palsy, cognitive delay, visual/hearing deficits), which significantly impact quality of life.

Prevention

• Primary:
  • Optimizing maternal health and nutrition: Reducing risks for preterm birth.
  • Promotion of maternal human milk: Education and support for pumping and lactation in mothers of preterm infants.
• Secondary:
  • Early aggressive PN: Rapid provision of protein and energy within 24 hours of birth to minimize catabolism and improve growth.
  • Initiation of minimal enteral nutrition (MEN) with human milk: Promotes gut maturation and reduces gut atrophy.
  • Standardized feeding protocols: Implementing evidence-based guidelines for advancing enteral feeds and fortifying human milk.
  • Regular monitoring of nutritional status: Anthropometrics, biochemical markers.
  • Prophylactic iron and vitamin D supplementation.
• Tertiary:
  • Aggressive management of growth failure: Intervening early with higher calorie/protein feeds, nutritional counseling.
  • Management of osteopenia of prematurity: Targeted calcium/phosphorus/vitamin D supplementation.
  • Treatment of PN-associated cholestasis: Specific lipid emulsions, ursodiol, cyclic PN.
  • Multidisciplinary follow-up: Involving dietitians, developmental specialists, pediatricians.

Special Populations

• ELBW/VLBW infants: Highest protein, calorie, calcium, phosphorus needs. Require most aggressive early PN and consistent human milk fortification. Highly susceptible to EUGR.
• Infants with Bronchopulmonary Dysplasia (BPD): Increased energy expenditure, often fluid restricted. May require concentrated formulas or higher calorie human milk fortifiers. Careful balancing of fluid and nutritional needs.
• Infants with Congenital Heart Disease (CHD): Often have increased metabolic demands and feeding difficulties. May require higher calorie feeds, continuous feeds, or gavage feeds. Fluid restriction may be necessary depending on cardiac physiology.
• Infants post-surgery (e.g., bowel resection, gastroschisis repair): May have malabsorption or prolonged ileus. Requires tailored nutrition, often prolonged PN, and specialized hydrolysate or elemental formulas. Ongoing monitoring for short bowel syndrome.
• Infants with specific metabolic disorders: Requires highly individualized, specialized formulas and diets under strict metabolic consultation.

Clinical Pearls

• Diagnostic:
  • Don't just look at weight: Head circumference and length are critical indicators of brain and skeletal growth, respectively. Disproportionate growth is a red flag.
  • "Growth velocity not just growth status": Focus on achieving target growth rates (e.g., 15-20 g/kg/day) rather than just a single weight measurement.
  • Elevated ALP in a preterm infant: Until proven otherwise, consider osteopenia of prematurity.
• Treatment:
  • "The gut is the best immune organ": Prioritize minimal enteral nutrition with human milk as early as possible to promote gut health and reduce NEC risk.
  • "Nutrition is medicine": Aggressive early nutrition is a therapeutic intervention, not just supportive care, especially for neurodevelopmental outcomes.
  • Human milk fortification is non-negotiable for VLBW infants: Unfortified human milk cannot meet their high nutrient needs.
  • Anticipate demands: Preterm infants are often anabolic; anticipate and provide higher protein and calorie targets than term infants.
• Pitfalls:
  • Delayed initiation of PN: Leads to significant protein catabolism and growth restriction.
  • Inadequate protein provision: Even if calories are met, insufficient protein limits tissue accretion.
  • Over-reliance on unfortified human milk: Leads to protein, calcium, and phosphorus deficiencies in VLBW infants.
  • Ignoring micronutrients: Deficiencies (e.g., vitamin D, iron) are common and preventable.
  • Rapid increases in enteral feeds: Can precipitate feeding intolerance and NEC. Gradual advancement is key.
  • Discharging infants with persistent growth failure: Requires close follow-up and often intensified outpatient nutritional support.

Recent Updates

• Guidelines:
  • European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) guidelines for parenteral and enteral nutrition in preterm infants continually updated (e.g., 2018 for PN, 2023 for enteral).
  • American Academy of Pediatrics (AAP) clinical reports and policy statements on nutritional management of preterm infants, including human milk and iron supplementation.
• Evidence:
  • Increased focus on individualized nutrition: Moving beyond one-size-fits-all, tailoring feeds based on specific infant needs and growth patterns.
  • Emerging evidence on specialized lipid emulsions for PN: Fish oil-based emulsions for reducing PNALD.
  • Role of targeted fortification: Adjusting fortifier based on individual milk analysis (hindmilk vs. foremilk, specific protein/fat content) to optimize nutrient delivery.
  • Studies on probiotics: Ongoing research into specific probiotic strains for NEC prevention; however, widespread recommendation still controversial due to safety concerns and strain specificity.
  • Long-term neurodevelopmental outcomes: Ongoing studies continue to demonstrate the critical link between early optimal nutrition and cognitive, motor, and behavioral development.
• Controversies:
  • Optimal timing and dosage of specific amino acids and lipids in PN: Ongoing debate and research.
  • Routine use of probiotics for NEC prevention: While some studies show benefit, concerns about sepsis risk in ELBW infants remain.
  • Optimal protein intake for ELBW infants: While higher intake is generally advocated, the maximal safe and beneficial dose is still being refined.
  • Best practice for post-discharge nutrition: Duration of specialized formulas/fortifiers, timing of introduction of solids.

Key References

• Guidelines:
  • ESPGHAN Committee on Nutrition (various clinical practice guidelines available on their website).
  • AAP Committee on Fetus and Newborn clinical reports and policy statements.
  • Cochrane Reviews on various aspects of preterm nutrition (e.g., early PN, human milk fortification, probiotics).
• Studies:
  • Fenton TR, Kim JH. A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. BMC Pediatrics. 2013;13:59.
  • Adams-Chapman I, Stoll BJ. Necrotising enterocolitis. Lancet. 2006 Dec 2;368(9550):1820-30. (Classic review on NEC)
  • EARLY PAN trial (e.g., Ziegler EE, et al. Early parenteral protein intake and weight gain in ELBW infants) - Landmark studies demonstrating benefit of early protein.
• Reviews:
  • Hay WW. Strategies for feeding the preterm infant. Neonatology. 2015;107(3):209-14.
  • Lapillonne A, Griffin IJ. Feeding Preterm Infants: Progress Toward Optimal Nutrition. J Pediatr. 2021 Jul;234S:S3-S7.

Disclaimer: This information is intended for educational purposes only and does not constitute medical advice. Clinical decisions for individual patients must always be made by a qualified healthcare professional, considering the patient's specific circumstances, current evidence, and institutional protocols. Medications, dosages, and treatment plans should be verified against the latest product information and national/international guidelines.